Clinical trials: Hepatic Malignancies
Hepatic Fibrosis, Hepatocellular Carcinoma
Magnetic Resonance Elastography (MRE) as a Predictor of HCC Recurrence After Radiofrequency Ablation (RFA)
The purpose of this study is to determine: The efficacy of MRE score as a predictor of HCC recurrence within 2 years after RFA treatment The efficacy of each indicator (MRE score, non-invasive serum markers) compared to the…
- Trial name
- MRE (NCT01447667)
- Testing
- Magnetic resonance elastography
- Where
- South Korea
- Volunteers
- 72 people
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma
Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma
Patients with liver cirrhosis and hepatocellular carcinoma will undergo transarterial chemoembolisation (TACE) as clinically indicated and will be randomized to receive bevacizumab or placebo every 2 weeks up to 1 year.
- Trial name
- NCT00280007
- Testing
- bevacizumab
- Where
- Austria
- Volunteers
- 32 people
- Sponsor
- Medical University of Vienna
Colorectal Cancer, Colorectal Carcinoma
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Determine the safety of a combination of IFN, celecoxib, and rintatolimod for patients with recurrent colorectal cancer. This will also test whether the above combination can help the immune system to fight the tumors.
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
- Trial name
- NCT01545141
- Testing
- Chemokin Modulatory Regimen (5 MU/m2), Chemokin Modulatory Regimen (10 MU/m2), Chemokin Modulatory Regimen (20 MU/m2)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Roswell Park Cancer Institute
Liver Metastasis Colon Cancer
Treatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM.
A few studies have documented that some patients can be down-staged from an initially inoperable state to a potentially resectable state.
- Trial name
- NCT04003792
- Testing
- oxaliplatin, FOLFIRI Protocol, Bevacizumab
- Where
- Israel
- Volunteers
- 49 people
- Sponsor
- Rabin Medical Center
Hepatic Carcinoma
ESP Block on Patient Outcomes in Patients With Liver Tumor Undergoing Radiofrequency Ablation
To evaluate the ability of Erector spina Plane Block decrease postoperative pain and analgesia requirements in patients undergoing percutaneous Radiofrequency ablation of Hepatocellular Carcinomas.
- Trial name
- NCT05009550
- Testing
- Group ESP, Non-blocked Group
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- TC Erciyes University
Intrahepatic Cholangiocarcinoma
HAIC Plus QL1706 & Bevacizumab in Unresectable HER2-Negative ICC
Intrahepatic cholangiocarcinoma (ICC) has an increasing global incidence, and over 70% of patients are diagnosed at unresectable stages with limited survival benefits from standard first-line chemotherapy regimens.
- Trial name
- NCT07841574
- Testing
- hepatic arterial infusion chemotherapy (HAIC) combine with QL1706 and bevacizumab
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Lianghe Lu
Colorectal Cancer, Hepatic Metastasis
Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer
The purpose of this study is to to evaluate the correlation of overall objective response according to RECIST v1.1. criteria evaluated by conventional imaging techniques, morphologic response by CT, and histopathologic response…
- Trial name
- AVAMET (NCT01493713)
- Testing
- Evaluate the correlation of overall different objective response.
- Where
- 21 sites in Spain
- Volunteers
- 83 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Neoplasms, Colorectal
A Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects With Colorectal Cancer and Hepatic Metastases
The primary purpose of this study is to determine the safety and tolerability of SRT501 (5.0 g) in subjects with colorectal cancer and hepatic metastases when administered once daily for 14 days.
- Trial name
- NCT00920803
- Testing
- SRT501
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- Sirtris, a GSK Company
Colorectal Cancer
Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
This research study is studying a drug in combination with radiation therapy as a possible treatment for hepatic metastases from colorectal cancer.
- Trial name
- NCT03223779
- Testing
- TAS-102, Photon SBRT
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Massachusetts General Hospital
Acute Liver Failure
Registry Protocol for Tracking Trial Subjects After VTI-206 Study Completion
VTI-207 (NCT01452295) is designed to follow subjects, both treated and control, for five years after their completion of study participation in protocol VTI-206 (NCT00973817) to gather information relating to the incidence of…
- Trial name
- NCT01452295
- Testing
- ELAD (Extracorporeal Liver Assist System)
- Sponsor
- Vital Therapies, Inc.
Breast Cancer
Setup Variation in the Supraclavicular Lymph Nodes Treatment in Breast Cancer Patients
The goal of this clinical research study is to use the On Board Imager kilovoltage (OBI KV) system and cone beam computed tomography (CBCT) scanning or CT-on-rail system to look at how well a routine device called an electronic…
- Trial name
- NCT00658281
- Testing
- CBCT Scan, OBI KV Imaging
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumor, Hepatic Impairment
Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment
Lurbinectedin is mainly eliminated by the liver. Thus, Hepatic Impairment (HI) may alter the plasma concentrations of lurbinectedin.
- Trial name
- NCT05101265
- Testing
- Lurbinectedin
- Where
- 6 sites in Spain
- Volunteers
- 24 people
- Sponsor
- PharmaMar
Hepatocellular Carcinoma
A Phase II Study of a Continuous Hepatic Arterial Infusion Combination Therapy With OPC-18 and 5-FU in Patients With Highly Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the safety and efficacy of a continuous hepatic arterial infusion combination therapy with OPC-18 and 5-FU versus BST in patients with highly advanced hepatocellular carcinoma for which…
- Trial name
- NCT00524498
- Testing
- OPC-18, cisplatin
- Where
- 7 sites in Japan
- Volunteers
- 60 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Colorectal Cancer, Metastatic Cancer
Flt3L in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Flt3L may stimulate a person's immune system and help kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of flt3L given to patients before undergoing surgery to remove metastases from colorectal cancer.
- Trial name
- NCT00003431
- Testing
- recombinant flt3 ligand
- Where
- United States
- Sponsor
- Duke University
Malignant Hepatobiliary Neoplasm
Endoscopic Ultrasonography Guided Biliary Drainage
Endoscopic ultrasonography is a widely accepted modality for the diagnosis of gastrointestinal and pancreatic-biliary diseases. Endoscopic ultrasonography-guided biliary drainage has attracted attention as an alternative…
- Trial name
- NCT03195075
- Testing
- Endoscopic ultrasonography guided biliary drainage, Percutaneous trans-hepatic biliary drainage
- Volunteers
- 40 people
- Sponsor
- Assiut University
HepatoCellular Carcinoma
Hepatic Arteriography in Liver Cancer Diagnosis and Staging Applications
Primary liver cancer is one of the most common malignant tumor and leading cause of cancer-related death worldwide. Basically therapeutic strategies were considered and given based on the staging of liver cancer.
- Trial name
- RDSA (NCT02936856)
- Testing
- Hepatic Arteriography
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Guangxi Medical University
Liver Tumour
Targeted Chemotherapy Using Focused Ultrasound for Liver Tumours
This proof of concept study proposes targeted delivery of a broad-spectrum cytotoxic agent (doxorubicin), via a specially formulated LTSL (ThermoDox®) activated by mild hyperthermia, by using focused ultrasound (FUS), to achieve…
- Trial name
- TARDOX (NCT02181075)
- Testing
- ThermoDox® (LTLD), Focused Ultrasound of Target Liver Tumour, Pre-LTLD Biopsy of Target Liver Tumour
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- University of Oxford
Liver Cancer
Irreversible Electroporation(IRE) For Unresectable Portal Venous Tumor Emboli
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Portal venous tumor emboli.
- Trial name
- IRE (NCT02333773)
- Testing
- Irreversible electroporation (IRE)
- Where
- China
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Hepatocellular Carcinomas
188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas
This study is to determine the maximum tolerated dose and the recommended 188Re-SSS Lipiodol activity for hepatic intra-arterial injection in patients with hepato-cellular carcinoma.
- Trial name
- LIP-RE-I (NCT01126463)
- Testing
- 188Re-SSS Lipiodol
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Center Eugene Marquis
Hepatocellular Carcinoma, Portal Vein Tumor Thrombosis
Transarterial Chemoembolization (TACE) With Radiation Therapy (RT) in Advanced Hepatocellular Carcinoma (HCC)
The presence of portal vein tumor thrombosis (PVTT) in patients with hepatocellular carcinoma (HCC) is one of the most significant prognostic factors for poor prognosis, without treatment, their survival is less than 3 months.
- Trial name
- NCT02290977
- Testing
- Scheduled interval TACE - RT
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Samsung Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.